The Medicare Advantage appeals process exists on paper as a five-stage system: the health plan reconsiders its own denial, then an independent review entity reconsiders, then an administrative law judge hears the case, then the Medicare Appeals Council reviews it, then federal district court. For a beneficiary with a denied claim, the process offers multiple opportunities for reversal.
What the process offers in practice is different. The time required to reach the ALJ stage — the first stage that involves a genuinely independent reviewer — is measured in months. The dollar threshold to access an ALJ hearing is $190 per claim as of 2026. The beneficiary must navigate filing deadlines, documentation requirements, and procedural rules that vary by stage. And the care that was denied — skilled nursing facility rehabilitation, home health services, a diagnostic imaging study — is typically needed now, not in six months when the ALJ schedules a hearing.
The appeals process is not designed around the urgency of care. It is designed around the administrative machinery of dispute resolution. When those two things conflict — as they do most often for the Medicare-eligible population, whose care needs are acute and whose administrative capacity is limited — the machinery wins.
The Denial Rate Record
Medicare Advantage plans deny prior authorization requests and payment claims at substantially higher rates than traditional Medicare. The federal government does not require MA plans to report denial rates in a standardized, publicly comparable format — a transparency gap that limits direct plan-to-plan comparison — but OIG, GAO, and congressional investigations have documented the overall pattern consistently.
OIG’s April 2022 report found that the 15 largest MA organizations, covering nearly 80 percent of MA beneficiaries, issued millions of denials each year, with 13 percent of prior authorization denials and 18 percent of payment denials meeting Medicare coverage criteria. The report identified the pattern as systemic, not incidental — the same causes appearing across plans and service types.
A 2023 KFF analysis of CMS data found that MA plans denied approximately 7 percent of in-network prior authorization requests in 2021 — a rate that, applied to the volume of MA authorization requests, represents millions of individual denials. The denial rate varied substantially across plans: some plans denied more than 15 percent of prior authorization requests, others fewer than 2 percent. The variation itself is informative — if prior authorization denials primarily reflected clinical judgment about medical necessity, the rates would not vary by an order of magnitude across plans serving similar populations.
The categories most heavily denied mirror what OIG identified in its 2022 report: post-acute care transfers, advanced imaging, and injections — the highest-cost categories in the outpatient and post-acute settings where the capitated payment structure creates the strongest financial incentive to deny.
Traditional Medicare denies claims too — it is not a rubber stamp for any service billed. But traditional Medicare applies a consistent set of national coverage determinations and local coverage determinations established through a public process, not plan-specific internal clinical criteria that can be more restrictive than Medicare’s own standards. The documented pattern of MA denials exceeding Medicare coverage criteria is not a comparison between a permissive and a rigorous system. It is a comparison between Medicare’s publicly established standards and MA plans’ internal standards, with the latter demonstrably more restrictive in ways OIG has found unjustified.
The Appeals Process: Five Stages, One Practical Barrier
The MA appeals process has five stages. Each stage has defined filing deadlines and decision timelines — but timelines for decisions are not the same as timelines for care.
Stage 1 — Health Plan Reconsideration. The plan that issued the denial reviews its own decision. For pre-service requests, the standard decision timeline is 30 days; expedited review is 72 hours. The reconsideration is conducted by the same organization whose financial interest produced the original denial. OIG found that plans spontaneously reversed only 3 percent of prior authorization denials without an appeal being filed — suggesting that the initial denial, in the overwhelming majority of cases, reflected a considered position rather than an administrative error.
Stage 2 — Independent Review Entity (IRE). If the plan upholds its denial at reconsideration, the beneficiary can appeal to a CMS-contracted independent review entity. The IRE applies Medicare coverage standards rather than plan-specific criteria. The 60-day standard decision timeline for payment denials means a beneficiary waiting for IRE review of a denied post-acute care claim may wait two months for a decision on care that was needed the week the hospital discharge occurred.
Stage 3 — Administrative Law Judge Hearing. The first stage involving a genuinely independent adjudicator. ALJ hearings have produced the strongest documented reversal rates in the Medicare appeals system: the American Hospital Association’s 2022 Medicare Appeals Survey, drawing on data from 150 member hospitals, found a 69 percent provider-favorable outcome rate at the ALJ stage — meaning roughly seven in ten cases that reached an ALJ resulted in reversal of the denial. That figure, for provider appeals, is broadly consistent with beneficiary appeal outcomes documented across the appeals system.
A 69 percent reversal rate at the ALJ stage is not evidence that the appeals process works. It is evidence that 69 percent of the denials that survived to the ALJ stage should not have been issued. The cases that reached the ALJ stage are a self-selected sample of denials serious enough and well-resourced enough to have been appealed through two prior stages. The population of improper denials that never reached Stage 3 is substantially larger — most denials are never appealed at all.
Stages 4 and 5 — Medicare Appeals Council and Federal District Court. Review options that exist primarily for cases involving substantial dollar amounts or significant legal questions. The amount in controversy threshold for federal district court review is $1,840 as of 2024. Most individual claims denials do not approach this threshold.
Who Actually Appeals
The fundamental problem with the MA appeals process is not procedural. It is behavioral. The population whose denials most warrant appeal is the population least able to pursue it.
The Medicare beneficiary facing a denied post-acute care authorization is typically in a hospital bed or a rehabilitation facility, recently discharged from surgery, managing pain, and navigating a transition of care with the help of family members who are simultaneously working and arranging logistics. The hospital discharge planner has a limited window to facilitate an expedited redetermination before the bed is needed. The beneficiary may not know they have appeal rights, may not understand the filing requirements, and may not have the energy, attention, or documentation to mount an effective appeal.
The result is a denial system that functions, in practice, as a deterrence system. The denial is issued. The beneficiary or provider may attempt a first-stage redetermination, which the plan upholds in the vast majority of cases. At that point, most appeals stop. The care is not received, or is received out-of-pocket, or is received at a lower level of care than the physician recommended. The appealed denial that reaches an ALJ and is reversed is the exception. The accepted denial is the rule.
KFF analysis of CMS data found that fewer than 1 percent of MA coverage denials in 2021 were appealed to any stage of the process. Among those that were appealed and reached IRE review, the overturn rate was approximately 80 percent. The combination of these two figures — near-zero appeal rate, high reversal rate when appealed — is the most concise description of what the MA denial system produces: a large volume of unjustified denials that generate financial benefit for the insurer because the vast majority are never challenged.
The Provider Burden
The denial and appeals burden falls not only on beneficiaries. It falls substantially on providers — the hospitals, skilled nursing facilities, physician practices, and home health agencies that deliver care to MA enrollees and then navigate the documentation, appeals, and write-offs that denied claims generate.
The American Medical Association’s 2025 Prior Authorization Physician Survey found that physicians and their staff spend an average of 14 hours per week on prior authorization activities — obtaining authorizations, appealing denials, managing the administrative interaction with MA plans. For a small physician practice, 14 hours per week of staff time devoted to insurance administration represents a substantial operational burden that ultimately affects the capacity available for patient care.
Hospitals and skilled nursing facilities face a different version of the same problem. When an MA plan denies a skilled nursing facility claim after the care has been delivered — a retroactive payment denial rather than a pre-service prior authorization denial — the facility must either absorb the cost or pursue an appeal. The appeal takes time and resources. Small facilities without dedicated billing and appeals staff are more likely to absorb the denial. Large health systems with specialized revenue cycle operations are more likely to appeal — which contributes to the documented pattern of denial reversal rates being higher for institutional providers than for individual beneficiaries.
The provider burden is not incidental. It is the mechanism by which a denial rate that would be unsustainable if routinely appealed becomes financially viable for the insurer. The insurer issues the denial. The provider weighs the cost of appealing against the probability of success and the amount in dispute. Smaller providers and individual beneficiaries absorb denials that larger providers would appeal. The population of denials that is effectively unchallenged is much larger than the population that is appealed.
The Enforcement Gap
CMS has authority to sanction MA plans for patterns of improper denials. The enforcement tools include civil monetary penalties, correction action plans, and — in extreme cases — contract termination or suspension of enrollment. The record of enforcement against MA plans for improper denial patterns is sparse relative to the documented scale of the problem.
OIG identified persistent problems with MA denial practices in reports in 2018 and 2022 and noted, in the 2022 report, that as of March 2022, CMS had not yet fully implemented OIG’s 2018 recommendations on oversight of MA denials. A four-year gap between a documented problem and incomplete implementation of recommended oversight changes is a measure of enforcement capacity, not of CMS’s commitment to the mission.
The civil monetary penalties available to CMS for MA plan violations are modest relative to the financial benefit the violations generate. An MA plan that improperly denies post-acute care claims across a large enrollment base generates margin on each denial that the denied claim would have consumed. A civil monetary penalty assessed months or years after the fact, covering a small fraction of the denied claims, does not change the financial calculus that produced the denials. The penalty is priced in as a cost of doing business. The denial remains the rational strategy.
The enforcement architecture does not match the scale of the problem it is nominally designed to address. That gap — between documented harm and enforcement response — is a consistent feature of the MA oversight system across every mechanism this hub documents: the overpayment, the marketing violations, and the denial record.
What the Record Shows
The MA denial and appeals record establishes several things that are individually documented and collectively decisive.
MA plans deny prior authorization requests and payment claims at rates that include a substantial proportion of medically justified care — OIG found 13 percent of PA denials and 18 percent of payment denials met Medicare coverage criteria in its 2022 review. The denials are concentrated in high-cost categories where the financial incentive to deny is strongest. The appeal process, when pursued to the ALJ stage, reverses the denial in approximately 69 percent of provider-appealed cases — documenting systematic over-denial, not clinical judgment. Fewer than 1 percent of denials are appealed to any stage. The enforcement response is a fraction of the financial benefit the denial pattern generates.
The aggregate picture is a denial system in which the financial architecture of the program — a capitated payment structure that rewards reduced care delivery — has produced a pattern of coverage denial that the appeals system, the oversight framework, and the enforcement machinery have not corrected and are not currently structured to correct.
Traditional Medicare does not operate a prior authorization system for most services. It does not have a denial-and-appeals apparatus that generates millions of contested decisions per year. It does not impose an administrative burden on providers that the AMA measures in hours per physician per week. Those are not features of a more rigorous coverage system. They are features of a privatization architecture whose financial interest is oriented against the beneficiary’s interest in comprehensive coverage.
The complete Medicare Advantage series
01 — What Medicare Advantage Actually Is — and How It Replaced Traditional Medicare
02 — The Political History: How Private Insurers Got Into Medicare
03 — The Marketing Machine: How Enrollment Works and Who It Targets
04 — Risk Adjustment: The Payment System That Rewards Diagnosis, Not Treatment
05 — The $84 Billion Overpayment: How Upcoding Works at Scale
06 — The Profit Extraction Model: What Insurers Take Before Care Is Delivered
07 — Prior Authorization in Medicare Advantage: What OIG Found
08 — The Denial and Appeals Record: What Happens When Enrollees Push Back
09 — Network Adequacy and the Coverage Gap
10 — The Extra Benefits Myth: Dental, Vision, and What the Fine Print Says
11 — When Medicare Advantage Fails: Disenrollment at the End of Life
12 — The Reform Proposals: From Audit Reform to Elimination
13 — What the Evidence Resolves — and What It Doesn’t
This article was researched and drafted with AI assistance under human review. See our full AI and editorial practices.